Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]

Schedule of Reportable Segment Revenue, Operating Expenses, and Net Loss

The Company's reportable segment revenue, operating expenses, and net loss for the years ended December 31, 2024 and December 31, 2023 are as follows:

	Year Ended December 31,
	2024			2023
Collaboration revenue	$	80,000		$	2,805
Operating expenses:
Research and development
Losmapimod external expenses		20,801			29,069
Pociredir external expenses		8,577			7,442
Employee compensation expenses (excluding stock-based compensation expenses)		15,347			16,978
Stock-based compensation expenses		4,653			3,776
Pre-development candidate expenses and unallocated expenses		14,008			14,536
General and administrative		36,448			41,668
Restructuring expenses		2,063			—
Total operating expenses		101,897			113,469
Loss from operations		(21,897	)		(110,664	)
Other income, net		12,172			13,329
Net loss	$	(9,725	)	$	(97,335	)